Flecainide Contraindications and Precautions

Absolute Contraindications

• The American Heart Association recommends that flecainide is absolutely contraindicated in patients with structural heart disease, particularly coronary artery disease, previous myocardial infarction, or reduced left ventricular ejection fraction due to increased risk of mortality and proarrhythmia 1, 2
• Flecainide is contraindicated in patients with structural heart disease, particularly with reduced left ventricular function, due to increased risk of mortality and proarrhythmia 1, 3
• The American College of Cardiology recommends that flecainide is contraindicated in patients with decompensated systolic heart failure/LV dysfunction 1
• History of myocardial infarction is a contraindication for flecainide use 2

Relative Contraindications and Precautions

Cardiac Conditions

• The American Heart Association recommends that flecainide should be used with caution in patients with sinus node dysfunction, as it may worsen sinus node activity 1
• Flecainide should be used with caution in patients with AV conduction disease, as it may increase the risk of complete heart block 1
• Wolff-Parkinson-White syndrome with atrial fibrillation/flutter is a relative contraindication for flecainide use 1

Non-Cardiac Conditions

• Renal dysfunction is a relative contraindication for flecainide use, as it is primarily eliminated through the kidneys 1
• Hepatic dysfunction is a relative contraindication for flecainide use 1

Drug Interactions

• The American Heart Association recommends that flecainide should not be used concomitantly with drugs that have SA and/or AV nodal-blocking properties 1
• Significant interactions with flecainide include amiodarone, digoxin, verapamil, clarithromycin, cyclosporine, erythromycin, itraconazole, posaconazole, propafenone, and voriconazole 1

Important Monitoring Considerations

• The European Society of Cardiology recommends that QRS duration should be monitored, and an increase >25% from baseline indicates potential proarrhythmic risk requiring dose reduction or discontinuation 2, 4
• Flecainide increases defibrillation energy requirements and pacing thresholds, requiring potential reprogramming of cardiac devices 4
• Flecainide can convert atrial fibrillation to slow atrial flutter with 1:1 AV conduction, which may be confused with ventricular tachycardia 4

Appropriate Use

• Flecainide should only be used in patients without structural heart disease 3
• The American College of Cardiology recommends that flecainide should only be used in patients with supraventricular tachyarrhythmias who have failed or cannot tolerate beta-blockers, diltiazem, or verapamil 3
• Flecainide may be used in carefully selected patients with atrial fibrillation for cardioversion, maintenance of sinus rhythm, or "pill-in-the-pocket" approach 2, 5

Pill-in-the-Pocket Flecainide Dosing for Atrial Fibrillation

Patient Selection and Treatment Protocol

• The American College of Cardiology recommends a single oral loading dose of 200-300 mg of flecainide for pill-in-the-pocket therapy in atrial fibrillation, administered at symptom onset after safety has been established during an initial in-hospital trial 6, 7
• Patients must meet specific selection criteria, including no structural heart disease, no ischemic heart disease or prior myocardial infarction, no sinus or AV node dysfunction, no bundle-branch block, and no QT-interval prolongation, to be eligible for pill-in-the-pocket flecainide therapy 6, 7
• An initial conversion trial must be undertaken in hospital before any patient is permitted to use pill-in-the-pocket therapy at home, due to the risk of major adverse effects, such as proarrhythmic events and bradycardia 6, 7, 8
• A beta-blocker or non-dihydropyridine calcium channel antagonist must be administered at least 30 minutes before the class IC agent, or prescribed as continuous background therapy, to prevent rapid AV conduction if atrial flutter develops with 1:1 conduction 6, 7, 9

Dosing and Efficacy

• The standard dosing protocol for pill-in-the-pocket flecainide therapy is 300 mg as a single oral dose, with an expected conversion time of 2 hours and resolution within 6 hours in 94% of episodes 6, 7
• The pill-in-the-pocket approach demonstrates a 94% success rate for conversion within 6 hours, 84% effectiveness in patients with recurrent episodes, and a significant reduction in emergency department visits and hospitalizations compared to conventional care 6, 7

Guideline Status

• The European Society of Cardiology guidelines on supraventricular tachycardia support the use of the pill-in-the-pocket approach for atrial fibrillation in appropriately selected patients, with the most robust evidence supporting its use specifically for paroxysmal atrial fibrillation in patients without structural heart disease 6, 7, 9, 10

ESC Guideline Recommendations for Rhythm‑Control Therapy in Patients with Coronary Artery Disease

Contraindication of Class IC Agents

• The 2024 European Society of Cardiology (ESC) atrial‑fibrillation guideline states that flecainide or propafenone should not be used in patients with coronary artery disease, making these drugs absolutely contraindicated in that population. 11

Evaluation of Flecainide Use

• According to the same ESC guideline, clinicians should reassess the original indication for flecainide (typically atrial fibrillation) and select an alternative rhythm‑control strategy when coronary artery disease is present. 11

Preferred Antiarrhythmic Alternatives

• Amiodarone is recommended by the 2024 ESC guideline as the antiarrhythmic of choice for patients with coronary artery disease who require rhythm control, including cardioversion. 11
• Dronedarone is also endorsed by the ESC guideline for patients with ischemic or valvular heart disease who need long‑term rhythm control to prevent atrial‑fibrillation recurrence and progression. 11

Non‑Pharmacologic Rhythm‑Control Options

• The ESC guideline advises that catheter ablation may be considered as a first‑ or second‑line therapy for rhythm control in patients who cannot receive Class IC agents because of coronary artery disease. 11